Literature DB >> 27362912

Electronic health record interventions at the point of care improve documentation of care processes and decrease orders for genetic tests commonly ordered by nongeneticists.

Maren T Scheuner1,2, Jane Peredo1, Kelly Tangney1, Diane Schoeff1, Taylor Sale1, Caroline Lubick-Goldzweig1,2, Alison Hamilton1,3, Lee Hilborne4,5, Martin Lee1, Brian Mittman1, Elizabeth M Yano1,6, Ira M Lubin7.   

Abstract

OBJECTIVE: To determine whether electronic health record (EHR) tools improve documentation of pre- and postanalytic care processes for genetic tests ordered by nongeneticists.
METHODS: We conducted a nonrandomized, controlled, pre-/postintervention study of EHR point-of-care tools (informational messages and template report) for three genetic tests. Chart review assessed documentation of genetic testing processes of care, with points assigned for each documented item. Multiple linear and logistic regressions assessed factors associated with documentation.
RESULTS: Preimplementation, there were no significant site differences (P > 0.05). Postimplementation, mean documentation scores increased (5.9 (2.1) vs. 5.0 (2.2); P = 0.0001) and records with clinically meaningful documentation increased (score >5: 59 vs. 47%; P = 0.02) at the intervention versus the control site. Pre- and postimplementation, a score >5 was positively associated with abnormal test results (OR = 4.0; 95% CI: 1.8-9.2) and trainee provider (OR = 2.3; 95% CI: 1.2-4.6). Postimplementation, a score >5 was also positively associated with intervention site (OR = 2.3; 95% CI: 1.1-5.1) and specialty clinic (OR = 2.0; 95% CI: 1.1-3.6). There were also significantly fewer tests ordered after implementation (264/100,000 vs. 204/100,000; P = 0.03), with no significant change at the control site (280/100,000 vs. 257/100,000; P = 0.50).
CONCLUSIONS: EHR point-of-care tools improved documentation of genetic testing processes and decreased utilization of genetic tests commonly ordered by nongeneticists.Genet Med 19 1, 112-120.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27362912      PMCID: PMC6504173          DOI: 10.1038/gim.2016.73

Source DB:  PubMed          Journal:  Genet Med        ISSN: 1098-3600            Impact factor:   8.822


  36 in total

1.  EASL clinical practice guidelines for HFE hemochromatosis.

Authors: 
Journal:  J Hepatol       Date:  2010-04-18       Impact factor: 25.083

2.  Examining the clinical use of hemochromatosis genetic testing.

Authors:  Matthew B Lanktree; Bruce B Lanktree; Guillaume Paré; John S Waye; Bekim Sadikovic; Mark A Crowther
Journal:  Can J Gastroenterol Hepatol       Date:  2015 Jan-Feb

3.  Significant differences among physician specialties in management recommendations of BRCA1 mutation carriers.

Authors:  S U Dhar; H P Cooper; T Wang; B Parks; S A Staggs; S Hilsenbeck; S E Plon
Journal:  Breast Cancer Res Treat       Date:  2011-04-05       Impact factor: 4.872

4.  Performance of referral recommendations in patients with chronic back pain and suspected axial spondyloarthritis.

Authors:  Henning Christian Brandt; Inge Spiller; In-Ho Song; Janis L Vahldiek; Martin Rudwaleit; Joachim Sieper
Journal:  Ann Rheum Dis       Date:  2007-04-24       Impact factor: 19.103

Review 5.  The risk of recurrent venous thromboembolism among heterozygous carriers of factor V Leiden or prothrombin G20210A mutation. A systematic review of prospective studies.

Authors:  Antonio Marchiori; Laura Mosena; Martin H Prins; Paolo Prandoni
Journal:  Haematologica       Date:  2007-08       Impact factor: 9.941

6.  Optimizing the identification of patients with axial spondyloarthritis in primary care--the case for a two-step strategy combining the most relevant clinical items with HLA B27.

Authors:  Annalina Braun; Holger Gnann; Ertan Saracbasi; Joachim Grifka; Uta Kiltz; Katrin Letschert; Jürgen Braun
Journal:  Rheumatology (Oxford)       Date:  2013-04-04       Impact factor: 7.580

7.  Good laboratory practices for molecular genetic testing for heritable diseases and conditions.

Authors:  Bin Chen; MariBeth Gagnon; Shahram Shahangian; Nancy L Anderson; Devery A Howerton; Joe D Boone
Journal:  MMWR Recomm Rep       Date:  2009-06-12

Review 8.  Factor V Leiden thrombophilia.

Authors:  Jody Lynn Kujovich
Journal:  Genet Med       Date:  2011-01       Impact factor: 8.822

9.  Effective communication of molecular genetic test results to primary care providers.

Authors:  Maren T Scheuner; Maria Orlando Edelen; Lee H Hilborne; Ira M Lubin
Journal:  Genet Med       Date:  2012-12-06       Impact factor: 8.822

10.  Population prevalence of familial cancer and common hereditary cancer syndromes. The 2005 California Health Interview Survey.

Authors:  Maren T Scheuner; Timothy S McNeel; Andrew N Freedman
Journal:  Genet Med       Date:  2010-11       Impact factor: 8.822

View more
  3 in total

1.  Integrating Germline Genetics Into Precision Oncology Practice in the Veterans Health Administration: Challenges and Opportunities.

Authors:  Maren T Scheuner; Kenute Myrie; Jane Peredo; Lori Hoffman-Hogg; Margaret Lundquist; Stephanie L Guerra; Douglas Ball
Journal:  Fed Pract       Date:  2020-08

Review 2.  Challenges and opportunities for integrating genetic testing into a diagnostic workflow: heritable long QT syndrome as a model.

Authors:  Ira M Lubin; Edward R Lockhart; Julie Frank; Vincent Y See; Sudhir Vashist; Carol Greene
Journal:  Diagnosis (Berl)       Date:  2019-07-09

Review 3.  From public health genomics to precision public health: a 20-year journey.

Authors:  Muin J Khoury; M Scott Bowen; Mindy Clyne; W David Dotson; Marta L Gwinn; Ridgely Fisk Green; Katherine Kolor; Juan L Rodriguez; Anja Wulf; Wei Yu
Journal:  Genet Med       Date:  2017-12-14       Impact factor: 8.822

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.